and paying to own the stock..huh..... target 160..185..low end
I look for a nice earnings and think gild is worth 155.00 to 160.00 a share. I do think gild will grow and should buy out certain cancer treating biotech firms and become a leader in that as well.
Ask for more safety data on that drug ,6 months more for them. Biomarin must be insane to try to use that type of drug for life long dosing.
Public displays is really why sarepta did not get approval last year and is why chris is gone and that is why everyone is silent....the deal
welcome to the first quarter government tax collection .. sell long term holding taxed...sell short term tax collection, sell short tax collecting..largest tax is short term any way.
BioMarin Pharma (NASDAQ: BMRN) announced completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for drisapersen, an investigational exon-skipping drug candidate for the treatment of the largest genetically defined subset of Duchenne muscular dystrophy (DMD). DMD is the most common fatal genetic disorder diagnosed in childhood, affecting approximately 1 in every 3,500 live male births with about 20,000 new cases diagnosed globally each year. Drisapersen induces the skipping of dystrophin exon 51, potentially providing a therapeutic benefit to DMD patients for whom skipping of exon 51 restores the proper dystrophin reading frame, corresponding to approximately 13% of DMD patients. The company intends to also submit an application for registration in the European Union in summer 2015.
"We believe drisapersen may offer a meaningful benefit to boys living with DMD whose mutations are amenable to exon 51 skipping. The totality of data on drisapersen contains three randomized, placebo-controlled, efficacy trials and two long term extension studies, which include some boys treated for approximately 3.4 years," said Camilla V. Simpson, Global Head of Regulatory Affairs, Pharmacovigilance. "With this application, BioMarin continues in its long-standing tradition of developing important therapies for those who are most in need. The submission of the NDA represents a significant milestone for BioMarin, and we appreciate the strong, collaborative effort of many hard working employees, investigators, patients and their families. We look forward to working with the U.S. Regulatory Authorities to thoroughly understand the data generated for this heterogenous and critically ill patient population and hopefully to bring this treatment to patients expeditiously."
Drisapersen has been granted Orphan and Fast Track status, as well as Breakthrough Therapy designation by the FDA.
DMD is caused by a mutation in the gene
I see nothing negative here ..very much under priced by far
I will buy sarepta under 13.00 as much as possible/